Showing results (921-930 of 3,376) with videos related to

Sort By:
Pageof 338
The Lancet. Oncology|December 16, 2011
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trialDavid Dearnaley, Isabel Syndikus, Georges Sumo, et al.
The Lancet. Oncology|December 20, 2011
Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trialNancy Y Lee, Qiang Zhang, David G Pfister, et al.
The Lancet. Oncology|February 10, 2012
Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trialAngela M Cheung, Lianne Tile, Savannah Cardew, et al.
The Lancet. Oncology|January 24, 2012
Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane StudyJ Sven D Mieog, James P Morden, Judith M Bliss, et al.
The Lancet. Oncology|September 5, 2008
Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II)Valerie A Jenkins, Laurence M Ambroisine, Louise Atkins, et al.
The Lancet. Oncology|September 21, 2007
COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trialLi-Yan Khor, Kyounghwa Bae, Alan Pollack, et al.
The Lancet. Oncology|March 30, 2012
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialKim Margolin, Marc S Ernstoff, Omid Hamid, et al.
The Lancet. Oncology|February 8, 2022
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trialMatthew R Smith, Howard I Scher, Shahneen Sandhu, et al.
The Lancet. Oncology|June 22, 2019
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind studyGeorgina V Long, Reinhard Dummer, Omid Hamid, et al.
The Lancet. Oncology|June 22, 2019
MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trialSepideh Saadatmand, H Amarens Geuzinge, Emiel J T Rutgers, et al.
Pageof 338